Breaking Boundaries: Accelerating Antibody Discovery and Development for In Vivo CAR-T

On November 4, Professor Jennifer Doudna, the 2020 Nobel Prize in Chemistry laureate, led her team to secure $82 million in funding for development.in vivoCAR-T. On November 5, in Chinain vivoCAR-T Newcomer IVACTA Biotechnology Completes Angel Round Financing of Over 100 Million RMB. From Overseas to China,in vivoCAR-T has achieved "two-way success" in the global market, with the industry's popularity visibly climbing.

In vivoCAR-T, namely in vivo CAR-T technology, does not require the collection of a patient's autologous T cells for ex vivo modification like traditional ex vivo CAR-T. Instead, it directly delivers the CAR gene to T cells in the body via a vector, transforming them in situ into CAR-T cells to exert therapeutic effects. Compared with traditional autologous CAR-T therapy, in vivo CAR-T offers advantages such as simpler manufacturing, lower costs, no need for lymphocyte depletion, and the possibility of repeated dosing. It is expected to become a new paradigm for "off-the-shelf" cell therapy, especially suitable for solid tumors, immunodeficient patients, and time-sensitive treatment scenarios. This technological breakthrough overcomes the bottlenecks of long preparation cycles, high costs, and reliance on specialized manufacturing centers associated with traditional therapies, significantly improving accessibility.

Despite the fact that in vivo CAR-T is still in the early stages of research and clinical trials, facing challenges such as targeting specificity, delivery efficiency, and safety (e.g., cytokine release syndrome), it represents a significant direction for the next generation of immunotherapy, with tremendous potential to treat hematologic malignancies and even solid tumors, as well as other disease scenarios (autoimmune diseases, rare diseases, etc.).

In order to acceleratein vivoDevelopment of CAR-T Therapy, PharmRing and IVACTA Biotechnology jointly invitedDerek Chen, Senior Director of IVACTA Biotechnology's Antibody Drug Discovery Department, and Ying Li, Director of IVACTA Biotechnology's Antibody PD Department, onNovember 26Arrive at the Yaoke Rongyun Live Broadcast Room, fromin vivoCAR-T Begins to Enter the World of Antibodies.

Derek Chen

Senior Director of Antibody Drug Discovery at IVACTA Biotechnology

Ying Li

Director of PD Department, IVACTA Biotechnology Antibody